Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lipocine Q3 2026 Results: Net Loss of $666K, Loss Narrows

Lipocine Inc. reported total revenues of $2.6 million for the nine months ended September 30, 2026, driven by a $2.1 million license fee. Despite the revenue increase, the company incurred a net loss of $7.0 million due to higher operating expenses, though it maintains sufficient capital to fund operations through November 2027.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.30.1
Profit before tax-0.7-3.2
Net income-0.7-3.2
EPS (diluted, $ a share)$-0.08$-0.59

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+1898.8%
Operating margin-37.9%
Source

10-Q filed with the SEC, NASDAQ: LPCN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lipocine Inc.: key numbers

Share price
$1.66Close, Nov 16
Market cap
$18.4M
Shares outstanding
11.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lipocine Inc.

All →
3:24 PM ET Form 4
Insider Buying

Lipocine CEO Mahesh V. Patel Buys $79.5K of Stock

Mahesh V. Patel, CEO, bought 50,000 shares of Lipocine Inc. at $1.58 to $1.60 a share (average $1.59) in 2 transactions, worth $79.5K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 211,495 (+13.4%).

Value
$79.5K
Shares
50,000
Average price
$1.59
Role
CEO
Holding change
+13.4%
Trade date
Nov 12, 2026 to Nov 13, 2026
6:04 AM ET 8-K
Business Update

Lipocine Business Update

Lipocine Inc. announced the dosing of the first participant in its BLOOM Phase 3 study of LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is expected to enroll approximately 120 participants and incorporates design improvements from a previous Phase 3 trial, with topline results expected in the second half of 2027.

9:36 AM ET 8-K
Financial Results

Lipocine Financial Results

Lipocine Inc. reported financial results for the third quarter of 2026, highlighting a net loss of $0.7 million and a cash position of $21.5 million as of September 30, 2026. The company also provided clinical updates, including the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO) in postpartum depression and the approval of TLANDO in Canada.

Term
Q3 2026
7:47 AM ET 8-K
Investor Presentation

Lipocine Investor Presentation

Lipocine Inc. has updated its corporate presentation for use in meetings with investors, analysts, and other stakeholders. The presentation was filed as Exhibit 99.1 to the 8-K and provides a strategic overview of the company's business and development pipeline.

6:11 AM ET 8-K
Regulatory Approval

Lipocine Regulatory Approval

Lipocine announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males. The product is licensed to Verity Pharmaceuticals, which plans to launch and commercialize the oral therapeutic in the Canadian market by the end of 2026.

Counterparty
Health Canada
8:28 PM ET Form 4
Insider Buying

Lipocine Insider John W. Higuchi Buys $55K of Stock

John W. Higuchi bought 25,007 shares of Lipocine Inc. at $2.15 to $2.23 a share (average $2.20) in 2 transactions, worth $55K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 241,365 (+7.1%).

Value
$55K
Shares
25,007
Average price
$2.20
Holding change
+7.1%
Trade date
Sep 29, 2026 to Sep 30, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.